financetom
Business
financetom
/
Business
/
Thyssenkrupp Nucera abandons US green hydrogen projects no longer deemed feasible -CEO
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Thyssenkrupp Nucera abandons US green hydrogen projects no longer deemed feasible -CEO
Aug 13, 2025 4:32 AM

(Reuters) -Thyssenkrupp Nucera is in intensive discussions with stakeholders in its U.S. projects and is abandoning those no longer deemed feasible due to tax and spending changes initiated by U.S. President Donald Trump, its CEO said on Wednesday.

Global demand for green hydrogen had stalled amid concern among clean-tech players over what Trump's policies would mean for the industry.

But Thyssenkrupp Nucera's chief executive Werner Ponikwar said the company had more clarity around the financial viability of U.S. projects after the enactment of U.S. legislation that eliminated some tax credits for low-carbon energy sources.

"We have sorted out all projects that have less chance of being realized due to the new framework conditions in the U.S.," Ponikwar said in a call with journalists after the company reported results.

Trump's sweeping spending and tax legislation has made it harder to develop green tech projects in the U.S. by effectively phasing out renewable energy tax credits after 2026 if projects have not started construction.

Ponikwar said that with projects still expected to receive funding if they start construction work before a revised end of 2027 deadline, Thyssenkrupp Nucera will be able to advance state-side projects, especially those in advanced stages.

"We are convinced that the hydrogen electrolysis market continues to offer enormous potential," Ponikwar said, while adding that the company needs to be more patient than initially hoped.

If U.S. projects do not come to fruition, Thyssenkrupp Nucera will utilize its U.S. resources "for other purposes", Ponikwar said, echoing his sentiments from December.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Diagnostic imaging services provider RadNet's Q3 revenue up 13.4%
Diagnostic imaging services provider RadNet's Q3 revenue up 13.4%
Nov 10, 2025
Overview * RadNet ( RDNT ) Q3 revenue grows 13.4% yr/yr to $522.9 mln * Adjusted EPS for Q3 misses analyst expectations * Company revises full-year guidance upwards for revenue and EBITDA Outlook * RadNet ( RDNT ) raises 2025 Imaging Center revenue guidance to $1.9 bln-$1.93 bln * Company increases 2025 Imaging Center adjusted EBITDA guidance to $276 mln-$284...
ASE Technology Reports 6.7% Increase in Revenue for October
ASE Technology Reports 6.7% Increase in Revenue for October
Nov 10, 2025
03:59 AM EST, 11/10/2025 (MT Newswires) -- ASE Technology ( ASX ) reported Monday revenue of 60.23 billion New Taiwan dollars ($1.94 billion) for October, up 6.7% from a year earlier. Assembly, testing, and material revenue for the month increased 22.9% year over year to NT$36.04 billion, the company said. ...
Monro Insider Bought Shares Worth $11,102,374, According to a Recent SEC Filing
Monro Insider Bought Shares Worth $11,102,374, According to a Recent SEC Filing
Nov 10, 2025
03:58 AM EST, 11/10/2025 (MT Newswires) -- Carl C Icahn, 10% Owner, on November 05, 2025, executed a purchase for 638,659 shares in Monro ( MNRO ) for $11,102,374. Following the Form 4 filing with the SEC, Icahn has control over a total of 5,078,573 common shares of the company, with 5,078,573 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/876427/000153949725002873/xslF345X05/ownership.xml ...
BridgeBio Pharma Insider Sold Shares Worth $3,888,999, According to a Recent SEC Filing
BridgeBio Pharma Insider Sold Shares Worth $3,888,999, According to a Recent SEC Filing
Nov 10, 2025
03:59 AM EST, 11/10/2025 (MT Newswires) -- Ronald J Daniels, Director, on November 06, 2025, sold 61,031 shares in BridgeBio Pharma ( BBIO ) for $3,888,999. Following the Form 4 filing with the SEC, Daniels has control over a total of 16,991 common shares of the company, with 16,991 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1743881/000147083125000297/xslF345X05/wk-form4_1762556613.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved